Which Gram‑negative rods are non‑lactose fermenters, how are they identified on MacConkey agar, and what are the recommended treatments for infections caused by these organisms?

Non-Lactose Fermenting Gram-Negative Rods: Identification and Treatment

Non-lactose fermenting Gram-negative rods appear as colorless or pale colonies on MacConkey agar (versus pink/red for lactose fermenters), with the most clinically significant organisms being Pseudomonas aeruginosa, Acinetobacter baumannii, Proteus species, Salmonella species, and Stenotrophomonas maltophilia. 1, 2

Key Organisms and MacConkey Agar Appearance

The primary non-lactose fermenters include:

• Pseudomonas aeruginosa (most common, 66.7% of non-lactose fermenting isolates) - appears as colorless colonies, often with metallic sheen and grape-like odor 1
• Acinetobacter baumannii (33.3% of isolates) - colorless colonies 1
• Proteus mirabilis (3.4% of isolates) - colorless with characteristic swarming motility 2
• Salmonella typhi (8.9% of isolates) - colorless colonies 2

These organisms fail to ferment lactose, so they cannot produce acid that would turn the pH indicator (neutral red) pink on MacConkey agar, resulting in colorless/pale colonies rather than the pink colonies seen with E. coli and Klebsiella 2.

Treatment Recommendations by Organism

For Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)

Polymyxin-based therapy (colistin or polymyxin B) combined with a carbapenem remains the recommended approach for CRPA infections, despite the organism's in vitro resistance to carbapenems. 3 The combination provides superior outcomes compared to monotherapy, particularly for severe infections.

Alternative regimens include:

• Ceftolozane-tazobactam for MDR/XDR P. aeruginosa (no clear advantage of combination over monotherapy) 3
• Ceftazidime-avibactam 2.5g IV q8h for carbapenem-resistant strains 4
• Aminoglycosides (amikacin preferred, 79.3% resistance to tobramycin noted) combined with beta-lactams for severe infections 1, 5

For community-acquired Pseudomonas infections in intra-abdominal sources, use piperacillin-tazobactam, ceftazidime, or cefepime combined with metronidazole for anaerobic coverage 6, 7.

For Carbapenem-Resistant Acinetobacter baumannii (CRAB)

For CRAB pneumonia, use colistin with or without carbapenems, plus adjunctive inhaled colistin therapy. 4 Do not use tigecycline monotherapy for CRAB pneumonia (strong recommendation against). 4

For CRAB bloodstream infections, use colistin-carbapenem combination therapy. 4

For sulbactam-susceptible CRAB with hospital-acquired/ventilator-associated pneumonia, ampicillin-sulbactam is suggested over polymyxins. 3 However, cefiderocol is conditionally recommended against for CRAB infections due to concerning mortality signals. 3

Treatment duration should be 2 weeks minimum for severe infections like VAP or bacteremia, especially with septic shock. 8

For Proteus and Salmonella Species

For susceptible Proteus mirabilis causing endocarditis or severe infections, use ampicillin (2g IV q4h) or penicillin (20 million units IV daily) combined with gentamicin (1.7 mg/kg q8h). 9

For Salmonella endovascular infections, third-generation cephalosporins combined with an aminoglycoside (gentamicin or amikacin) are recommended, with cardiac surgery often required. 9

General Principles for Non-Lactose Fermenters

Piperacillin-tazobactam demonstrates the highest sensitivity (87% efficacy) against non-lactose fermenting uropathogens and should be considered first-line for susceptible organisms. 5

For empiric therapy pending susceptibility results:

• Amikacin or ciprofloxacin (for non-Pseudomonas species) are most effective empiric choices 10
• Avoid fluoroquinolones in areas with >10% E. coli resistance 6
• Prolonged infusion of beta-lactams is recommended for organisms with high MICs 4

Critical Pitfalls to Avoid

1. Do not assume carbapenem resistance means carbapenems are ineffective - for CRPA and CRAB, carbapenem combinations with polymyxins still provide benefit 4, 3

2. Multidrug resistance is the rule, not the exception - 63.5% of non-lactose fermenters show aminoglycoside resistance, with armA gene present in 97.7% of resistant isolates 1

3. Source control is paramount - antimicrobial therapy alone is insufficient without drainage, debridement, or device removal 11

4. Infectious disease consultation is strongly recommended for all MDRO infections 4

5. Obtain cultures before starting antibiotics when possible, as susceptibility testing is essential for definitive therapy given high resistance rates 4, 6